AIP
HUMA icon

Ameritas Investment Partners’s Humacyte HUMA Stock Holding History

Ameritas Investment Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.76K Hold
12,796
– – ﹤0.01% 2912
2025
Q4 		$12.3K Hold
12,796
– – ﹤0.01% 2847
2025
Q3 		$22.3K Hold
12,796
– – ﹤0.01% 2609
2025
Q2 		$26.7K Buy
12,796
+4,184
+49% +$8.04K ﹤0.01% 2529
2025
Q1 		$14.7K Hold
8,612
– – ﹤0.01% 2678
2024
Q4 		$43.5K Hold
8,612
– – ﹤0.01% 2269
2024
Q3 		$46.8K Hold
8,612
– – ﹤0.01% 2229
2024
Q2 		$41.3K Buy
8,612
+3,908
+83% +$20.3K ﹤0.01% 2243
2024
Q1 		$14.6K Hold
4,704
– – ﹤0.01% 2685
2023
Q4 		$13.4K Hold
4,704
– – ﹤0.01% 2748
2023
Q3 		$13.8K Hold
4,704
– – ﹤0.01% 2698
2023
Q2 		$13.5K Hold
4,704
– – ﹤0.01% 2778
2023
Q1 		$14.5K Hold
4,704
– – ﹤0.01% 2576
2022
Q4 		$12.4K Buy
4,704
+3,381
+256% +$10.3K ﹤0.01% 2748
2022
Q3 		$4K Hold
1,323
– – ﹤0.01% 2946
2022
Q2 		$4K Buy
+1,323
New +$7.36K ﹤0.01% 2977

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ameritas Investment Partners's HUMA Position: Q1 2026 in Review

Ameritas Investment Partners held its Humacyte (HUMA) position steady in Q1 2026 at 12,796 shares worth $7.76K. The position accounts for ﹤0.01% of the portfolio, ranked #2912.

Ameritas Investment Partners first reported a position in HUMA in Q2 2022 and has held it in 16 quarters since. The position peaked at $46.8K in Q3 2024. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Ameritas Investment Partners held 12,796 shares of Humacyte worth $7.76K as of Q1 2026.
  • Ameritas Investment Partners left its Humacyte share count unchanged in Q1 2026.
  • Humacyte made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2912 holding.
  • Ameritas Investment Partners first reported a position in Humacyte in Q2 2022 and has held it in 16 quarters since.
  • Ameritas Investment Partners's Humacyte position peaked at $46.8K in Q3 2024.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.